Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future

Adrian M.J. Pokorny; Venessa T. Chin; Adnan M. Nagrial; Desmond Yip; Lorraine A. Chantrill

doi:10.1111/imj.13810

Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future

Adrian M.J. Pokorny, Venessa T. Chin, Adnan M. Nagrial, Desmond Yip, Lorraine A. Chantrill^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

Abstract

Metastatic pancreatic ductal adenocarcinoma (mPDAC) is a lethal disease with a poor 5-year survival. Systemic treatments can be used to control symptoms and prolong life. Cytotoxic chemotherapies are commonly administered, with combination treatments, such as fluorouracil, folinic acid, irinotecan and oxaliplatin (FOLFIRINOX) or nab-paclitaxel and gemcitabine showing the largest clinical benefits. Newer genomic classifications of PDAC may provide a rationale for targeted therapies or immunotherapies, although at present these remain largely experimental. This review discusses the evidence behind the currently used regimens, while introducing the potential future of pancreatic cancer care.

Original language	English
Pages (from-to)	637-644
Number of pages	8
Journal	Internal Medicine Journal
Volume	48
Issue number	6
DOIs	https://doi.org/10.1111/imj.13810
Publication status	Published - Jun 2018

Access to Document

10.1111/imj.13810

Cite this

@article{edeff81e68214b1693708f40619c58aa,

title = "Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future",

abstract = "Metastatic pancreatic ductal adenocarcinoma (mPDAC) is a lethal disease with a poor 5-year survival. Systemic treatments can be used to control symptoms and prolong life. Cytotoxic chemotherapies are commonly administered, with combination treatments, such as fluorouracil, folinic acid, irinotecan and oxaliplatin (FOLFIRINOX) or nab-paclitaxel and gemcitabine showing the largest clinical benefits. Newer genomic classifications of PDAC may provide a rationale for targeted therapies or immunotherapies, although at present these remain largely experimental. This review discusses the evidence behind the currently used regimens, while introducing the potential future of pancreatic cancer care.",

keywords = "adenocarcinoma, cancer genomics, clinical trials, cytotoxic chemotherapy, metastatic, pancreatic cancer",

author = "Pokorny, {Adrian M.J.} and Chin, {Venessa T.} and Nagrial, {Adnan M.} and Desmond Yip and Chantrill, {Lorraine A.}",

note = "Publisher Copyright: {\textcopyright} 2018 Royal Australasian College of Physicians",

year = "2018",

month = jun,

doi = "10.1111/imj.13810",

language = "English",

volume = "48",

pages = "637--644",

journal = "Internal Medicine Journal",

issn = "1444-0903",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "6",

}

TY - JOUR

T1 - Metastatic pancreatic ductal adenocarcinoma

T2 - diagnosis and treatment with a view to the future

AU - Pokorny, Adrian M.J.

AU - Chin, Venessa T.

AU - Nagrial, Adnan M.

AU - Yip, Desmond

AU - Chantrill, Lorraine A.

PY - 2018/6

Y1 - 2018/6

N2 - Metastatic pancreatic ductal adenocarcinoma (mPDAC) is a lethal disease with a poor 5-year survival. Systemic treatments can be used to control symptoms and prolong life. Cytotoxic chemotherapies are commonly administered, with combination treatments, such as fluorouracil, folinic acid, irinotecan and oxaliplatin (FOLFIRINOX) or nab-paclitaxel and gemcitabine showing the largest clinical benefits. Newer genomic classifications of PDAC may provide a rationale for targeted therapies or immunotherapies, although at present these remain largely experimental. This review discusses the evidence behind the currently used regimens, while introducing the potential future of pancreatic cancer care.

AB - Metastatic pancreatic ductal adenocarcinoma (mPDAC) is a lethal disease with a poor 5-year survival. Systemic treatments can be used to control symptoms and prolong life. Cytotoxic chemotherapies are commonly administered, with combination treatments, such as fluorouracil, folinic acid, irinotecan and oxaliplatin (FOLFIRINOX) or nab-paclitaxel and gemcitabine showing the largest clinical benefits. Newer genomic classifications of PDAC may provide a rationale for targeted therapies or immunotherapies, although at present these remain largely experimental. This review discusses the evidence behind the currently used regimens, while introducing the potential future of pancreatic cancer care.

KW - adenocarcinoma

KW - cancer genomics

KW - clinical trials

KW - cytotoxic chemotherapy

KW - metastatic

KW - pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=85048359625&partnerID=8YFLogxK

U2 - 10.1111/imj.13810

DO - 10.1111/imj.13810

M3 - Article

SN - 1444-0903

VL - 48

SP - 637

EP - 644

JO - Internal Medicine Journal

JF - Internal Medicine Journal

IS - 6

ER -

Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future

Abstract

Access to Document

Other files and links

Fingerprint

Cite this